Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).Himisha Beltran, Noura J. Choudhury, Afshin Dowlati et al.|Journal of Clinical Oncology|2024Cited by 37
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).Himisha Beltran, Noura J. Choudhury, Afshin Dowlati et al.|Journal of Clinical Oncology|2024Cited by 30
698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)Noura J. Choudhury, Himisha Beltran, Banmeet S. Anand et al.|Annals of Oncology|2023Cited by 10